Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience
Figure 1
Immunosuppressive regimens of patients 1, 2, and 4 (panels (a)–(c), resp.) from the day of first preoperative treatment until postoperative day 20. Arrows indicate plasmapheresis or immunoadsorption; grey, green, and khaki colored areas correspond to maintenance therapy with prednisolone, tacrolimus, and adjuvant immunosuppression, respectively; blue and red area corresponds to induction treatment with daclizumab (100 mg at ALDLT and 50 mg on the seventh postoperative day) or antithymocyte globulin (1.5 mg per kilogram body weight) for 10 days and methylprednisolone (500 mg), respectively. PP: plasmapheresis; OP: relaparotomy.
